RegeneRx Technology:

RegeneRx’s novel technology platform utilizes Thymosin Beta 4 (Tß4), a synthetic copy of a naturally-occuring human peptide that plays a vital role in tissue regeneration. The Company is developing drug candidates in three principal areas: dermal, ophthalmic and cardiovascular wound healing.

Learn more

Wound Healing Animation: Acute vs Chronic Wound

View our corporate fact sheet

View our corporate presentations

August 20, 2008
RegeneRx Completes Patient Enrollment of First Phase II Clinical Trial

July 3, 2008
RegeneRx Completes Enrollment and Dosing of Phase IA Safety Trial for Potential Heart Drug

July 2, 2008
RegeneRx Receives Second $100,000 Award from State of Maryland to Develop Novel Treatment for Cardiac Reperfusion Injury